First-line trifluridine-tipiracil-bevacizumab versus capecitabine-bevacizumab for mCRC in patients ineligible for intensive therapy

Trifluridine-tipiracil plus bevacizumab has shown efficacy in phase 2 studies including patients with unresectable metastatic colorectal cancer (mCRC). The multinational phase 3 SOLSTICE study compared first-line trifluridine-tipiracil –bevacizumab versus capecitabine-bevacizumab for unresectable mCRC in patients who were ineligible for intensive therapy. There was no significant PFS difference between the two regimes. As expected, the safety profile differed between the treatments, but there were no new safety concerns. The authors conclude that first-line trifluridine-tipiracil-bevacizumab is a feasible alternative to capecitabine-bevacizumab in this population.